Moreover, there are many FDA-approved targeted medications for hereditary angioedema, such as a plasma-derived C1-INH, a plasma kallikrein inhibitor (Ecallantide), and a selective bradykinin-2 receptor antagonist (Icatibant). This evidence concerns the gene SERPING1 and hereditary angioedema.